Table 1.
Main demographic characteristics and relevant clinical data are reported in the table.
| Variable | Total | Progression disease | Stable disease | Partial response |
|---|---|---|---|---|
| No. of patients | 32 | 14 | 10 | 8 |
| Age (years) | 70 (29, 84) | 67,5 (45, 82) | 58 (29–79) | 74 (54–84) |
| Sex (F, M) | 9 F,23 M | 6 F, 8 M | 3 F, 7 M | 8 M |
| No. of metastatic sites [≥3 (N), <3 (N)] |
≥ (5), < (27) | ≥ (3), < (11) | ≥ (2), < (8) | ≥ (0), < (8) |
| LDH pre therapy (UI/L) | 389 (238, 827) | 450 (313, 827) | 331.9 (305–564) | 367.5 (238–602) |
| LDH post therapy (UI/L) | 419 (154, 803) | 503 (202, 803) | 390 (216–552) | 287.5 (154–475) |
| LDH percentage Variation (%) |
−3.73 (−50.16, 33.96) | 9.28 (−49.6, 23.32) | −5.42 (−34.7–33.9) | −19.1 (−50.2–10.5) |
| ECOG | 1 (0, 2) | 1 (1, 2) | 1 (0, 2) | 0 (0, 1) |
| Hepatic lesions | Yes (9), No (23) | Yes (3), No (11) | Yes (3), No (7) | Yes (3), No (5) |
| Lung lesions | Yes (14), No (18) | Yes (9), No (5) | Yes (4), No (6) | Yes (5), No (13) |
| Mean target lesions size (mm) | 30.4 (10, 140) | 45.3 (10, 140) | 38.7 (10, 88) | 28.5 (10–40.3) |
| OS median/range (months) | 31.6/2.73–66.8 | 20.6/2.73–48.6 | 38.6/3.5–56.6 | 54.6/29.3–66.8 |
| PFS median/range (months) | 15.1/2.5–52.7 | 5.3/2.6–24.3 | 23/2.5–50 | 46.1/13.2–52.6 |
| Death | Yes (17), No (15) | Yes (12), No (2) | Yes (2), No (8) | Yes (3), No (5) |